

Method

Models of human core transcriptional regulatory circuitries

Violaine Saint-André,^{1,5} Alexander J. Federation,^{2,5} Charles Y. Lin,² Brian J. Abraham,¹ Jessica Reddy,^{1,3} Tong Ihn Lee,¹ James E. Bradner,^{2,4} and Richard A. Young^{1,3}

¹Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA; ²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; ³Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA; ⁴Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA

A small set of core transcription factors (TFs) dominates control of the gene expression program in embryonic stem cells and other well-studied cellular models. These core TFs collectively regulate their own gene expression, thus forming an interconnected auto-regulatory loop that can be considered the core transcriptional regulatory circuitry (CRC) for that cell type. There is limited knowledge of core TFs, and thus models of core regulatory circuitry, for most cell types. We recently discovered that genes encoding known core TFs forming CRCs are driven by super-enhancers, which provides an opportunity to systematically predict CRCs in poorly studied cell types through super-enhancer mapping. Here, we use super-enhancer maps to generate CRC models for 75 human cell and tissue types. These core circuitry models should prove valuable for further investigating cell-type-specific transcriptional regulation in healthy and diseased cells.

[Supplemental material is available for this article.]

The pathways involved in complex biological processes such as metabolism have been mapped through the efforts of many laboratories over many years and have proven exceptionally valuable for basic and applied science (Krebs 1940; Kanehisa et al. 2012). Although we know much about the general mechanisms involved in control of gene transcription (Roeder 2005; Rajapakse et al. 2009; Bonasio et al. 2010; Conaway and Conaway 2011; Novershtern et al. 2011; Adelman and Lis 2012; Peter et al. 2012; Spitz and Furlong 2012; Zhou et al. 2012; de Wit et al. 2013; Gifford et al. 2013; Kumar et al. 2014; Levine et al. 2014; Ziller et al. 2014; Dixon et al. 2015; Tsankov et al. 2015), the complex pathways involved in the control of each cell's gene expression program have yet to be mapped in most cells. For some cell types, it is evident that core transcription factors (TFs) regulate their own genes and many others, forming the central core of a definable pathway. For most mammalian cell types, however, we have limited understanding of these pathways. These gene control pathways are important to decipher because they have the potential to define cell identity, enhance cellular reprogramming for regenerative medicine, and improve our understanding of transcriptional dysregulation in disease.

There is considerable evidence that the control of cell-type-specific gene expression programs in mammals is dominated by a small number of the many hundreds of TFs that are expressed in each cell type (Graf and Enver 2009; Buganim et al. 2013; Lee and Young 2013; Morris and Daley 2013). These core TFs are generally expressed in a cell-type-specific or lineage-specific manner and can reprogram cells from one cell type to another. In embryonic stem cells (ESCs), where transcriptional control has been

most extensively studied, the core TFs POU5F1 (also known as OCT4), SOX2, and NANOG have been shown to be essential for establishment or maintenance of ESC identity and are among the factors capable of reprogramming cells into ESC-like induced pluripotent stem cells (iPSCs) (Young 2011). These core TFs bind to their own genes and those of the other core TFs, forming an interconnected auto-regulatory loop (Boyer et al. 2005), a property that is shared by the core TFs of other cell types (Odom et al. 2004, 2006; Sanda et al. 2012). The core TFs and the interconnected auto-regulatory loop they form have been termed “core regulatory circuitry” (CRC) (Boyer et al. 2005). Because the ESC core TFs also bind to a large portion of the genes that are expressed in an ESC-specific manner, we can posit that regulatory information flows from the CRC to this key portion of the cell's gene expression program, thus forming a map of information flow from CRC to cell-type-specific genes (Young 2011).

With limited knowledge of CRCs in most cell types, attempts to map the control of gene expression programs have thus far been dominated by efforts to integrate global information regarding gene-gene, protein-protein, gene-protein, and regulatory element interactions nested in these networks (Lefebvre et al. 2010; Gerstein et al. 2012; Neph et al. 2012; Yosef et al. 2013; Kemmeren et al. 2014; Rolland et al. 2014). These global studies have provided foundational resources and important insights into basic principles governing transcriptional regulatory networks. These include the identification of recurring motifs of regulatory interactions (Lee et al. 2002; Alon 2007; Davidson 2010; Stergachis et al. 2014) and of groups of genes that participate in common biological processes (Bar-Joseph et al. 2003; Dutkowski et al. 2013).

⁵These authors contributed equally to this work.

Corresponding authors: young@wi.mit.edu, violaine.saintandre@gmail.com, james_bradner@dfci.harvard.edu

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.197590.115>.

© 2016 Saint-André et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genome.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

However, these network maps do not generally capture the notion that key control information flows from a small number of core TFs. Recent studies have revealed that core TFs bind clusters of enhancers called super-enhancers and that the super-enhancer (SE)-associated genes include those encoding the core TFs themselves (Hnisz et al. 2013, 2015; Whyte et al. 2013). The ability to identify super-enhancer-associated TF genes, and thus candidate core TFs, should permit modeling of CRCs for all human cell types for which super-enhancer data are available.

Here we describe a method to reconstruct cell-type-specific CRCs based on the properties of core TFs identified in ESCs and several other cell types: They are encoded by genes whose expression is driven by super-enhancers, and they bind to each other's super-enhancers in an interconnected auto-regulatory loop. We report CRC models for 75 cell and tissue types throughout the human body. These models recapitulate and expand on previously described CRCs for well-studied cell types and provide core circuitry models for a broad range of human cell types that can serve as a first step to further mapping of cell-type-specific gene expression control pathways.

Results

Models of core regulatory circuitry

To construct core regulatory circuitry models of human cell types, we used the logic outlined in Figure 1. Detailed studies of the transcriptional control of cell identity in ESCs and a few other cell types have shown that core TFs have three properties. Core TFs are encoded by genes associated with super-enhancers (Hnisz et al. 2013; Whyte et al. 2013), bind the SEs associated with their own gene (Whyte et al. 2013), and form fully interconnected auto-regulatory loops with the other core TFs by binding enhancers together with the other core TFs (Fig. 1A; Odom et al. 2004, 2006; Boyer et al. 2005; Sanda et al. 2012). Candidate core TFs were predicted for multiple cell and tissue types using these three criteria, as described below.

For 75 human cell and tissue types, we first identified the set of active genes that encode TFs that are proximal to SEs (Fig. 1B, step 1). SEs have high levels of signal density for H3K27ac and were identified from H3K27ac ChIP-seq data compiled from multiple laboratories (Supplemental Table S1), as previously described (Hnisz et al. 2013). Recent chromatin conformation data indicate that SEs generally interact with the proximal active gene (Downen et al. 2014), so the proximal active gene, identified through H3K27ac density at its TSS (see Methods), was assigned as the regulatory target of each SE.

Previous studies have shown that core TFs bind their own super-enhancers

(Hnisz et al. 2013; Whyte et al. 2013), so we next identified the set of SE-assigned TF genes whose products are predicted to bind their own SEs (Fig. 1B, step 2). Binding was predicted by searching SE constituents for DNA sequence motifs corresponding to the TF product of the gene assigned to that SE. We compiled DNA-binding sequence motifs for 695 TFs from multiple published sources (Supplemental Table S2; Berger et al. 2008; Wei et al. 2010; Robasky and Bulyk 2011; Jolma et al. 2013; Mathelier et al. 2014) and scanned SE constituent sequences for the presence of the TF binding motifs, using the FIMO software package from the MEME suite (Grant et al. 2011). SE constituents were used for the motif search, as TF binding distributions peak on the SE constituent sequences defined by H3K27ac ChIP-seq peak signal (Fig. 1C). Furthermore, the presence of multiple DNA sequence motifs at SE constituents is predictive of the binding of a TF, whereas this is not the case, on average, across the genome (Fig. 1D). This confirms previous observations of better TF binding prediction in open chromatin sequences compared to other regions of the genome (Pique-Regi et al. 2011; Zhong et al. 2013). We considered the SE-assigned TF genes that were predicted to bind their own SE as




Figure 1. A method to build core regulatory circuitry. (A) Graphical description of the method used to create core regulatory circuitry (CRC) models. 1. Identification of SE-assigned expressed TFs. 2. Identification of the TFs that are predicted to bind their own SE, considered as auto-regulated. 3. CRCs are assembled as fully interconnected loops of auto-regulated TFs. (B) Cartoon showing: 1. TF-assigned SE constituents defined by H3K27ac ChIP-seq peak signals; 2. TFs having at least three DNA-binding sequence motif instances in their SE constituents are considered auto-regulated; 3. TFs with SEs having at least three DNA-binding sequence motif instances for each of the other predicted auto-regulated TFs together form an interconnected auto-regulatory loop. (C) Metagenes for the ChIP-seq signal for H3K27ac (left) and for the average ChIP-seq signal for POU5F1, SOX2, and NANOG (right) in H1 hESCs in the region ± 5 kb around the center of the SE constituents. (D) Average percentage of DNA-binding motifs that are actually bound by the TFs from ChIP-seq data for POU5F1, SOX2, and NANOG in H1 hESCs, in either SE constituents or sets of random genomic sequences of the same size. (E) Venn diagram showing the average numbers, across 84 samples, of: 1. TFs having motifs that are expressed (445 TFs); 2. TFs having motifs that are expressed and assigned to a SE (61 TFs); 3. TFs having motifs that are expressed and assigned to a SE and that are predicted to bind their own SE (39 TFs); 4. TFs that are part of the CRC model (15 TFs).

auto-regulated, as prior evidence in ESCs indicates that such genes do regulate their own expression (Tomioka et al. 2002; Okumura-Nakanishi et al. 2005; Navarro et al. 2012).

To identify the SE-assigned TFs able to form an interconnected auto-regulatory loop by binding to each other's super-enhancers, we next identified, from the set of TFs considered auto-regulated, the TFs that are predicted to bind the SE of the other auto-regulated TFs, through a motif analysis in SE constituent sequences (Fig. 1B, step 3). We assembled interconnected auto-regulatory loops for each cell or tissue type (Fig. 1A, step 3) and selected the loop containing the set of TFs most often represented across the set of loops as the representative model of CRC (Supplemental Fig. S1). On average, across 75 cell types, 15% of the genes considered expressed and encoding TFs were assigned to an SE, 9% were predicted to be auto-regulated, and 3% were identified as candidate core TFs (Fig. 1E; Supplemental Table S3).

hESC core regulatory circuitry

The model of CRC predicted for human H1 ESCs (Fig. 2A, left panel) indicates that the approach described here captures the previously described core TFs and CRC for ESCs and suggests that additional TFs contribute to this core circuitry. The H1 ESC CRC contains three factors—POU5F1, SOX2, and NANOG—that are considered the foundation of the CRC in ESCs (Jaenisch and Young 2008; Young 2011). All three factors are essential for the pluripotent state (Nichols et al. 1998; Niwa et al. 2000; Avilion et al. 2003; Chambers et al. 2003; Mitsui et al. 2003; Masui et al. 2007; Silva et al. 2009; Theunissen et al. 2011), regulate their own genes and those encoding the other two factors (Tomioka et al. 2002; Catena et al. 2004; Boyer et al. 2005; Chew et al. 2005; Kuroda et al. 2005; Okumura-Nakanishi et al. 2005; Rodda et al. 2005; Loh et al. 2006), and can be used to reprogram fibroblasts to an induced pluripotent state (Takahashi and Yamanaka 2006; Yu et al. 2007).

The results of the algorithm we describe suggest that seven additional TFs contribute to the ESC CRC (Fig. 2A, left panel). Most of these factors have previously been implicated in control of the stem cell state, and there is ChIP-seq evidence indicating that their super-enhancers are bound by POU5F1, SOX2, and NANOG (Fig. 2B). FOXO1 and ZIC3 have previously been shown to be essential for the maintenance of pluripotency (Lim et al. 2007; Zhang et al. 2011; Declercq et al. 2013). In hESCs, FOXO1 regulates *POU5F1* and *SOX2* expression (Zhang et al. 2011). ZIC3 directly activates *Nanog* expression in mouse ESCs (mESCs) and can contribute to reprogramming of human fibroblasts into an induced pluripotent state (Lim et al. 2007; Declercq et al. 2013). NR5A1 (also known as SF1) and RARG can influence the pluripotent state (Guo and Smith 2010; Wang et al. 2011), and both bind to regulatory regions of the *POU5F1* gene and regulate its expression (Barnea and Bergman 2000; Yang et al. 2007; Guo and Smith 2010). The other three TFs—MYB, RORA, and SOX21—are best known for their roles in other stem cells. MYB and RORA have roles in establishing or maintaining self-renewing populations of hematopoietic cells (White and Weston 2000; Lieu and Reddy 2009; Cheasley et al. 2011; Zuber et al. 2011; Doulatov et al. 2013), while SOX21 is involved in regulating pluripotency in intestinal stem cells, where its expression is influenced by SOX2 (Kuzmichev et al. 2012). Thus, there are multiple lines of evidence, summarized in Table 1, that support the inclusion of POU5F1, SOX2, NANOG, FOXO1, ZIC3, NR5A1, RARG, MYB, RORA, and SOX21 in a model of hESC CRC.




Figure 2. H1 ESC core and extended regulatory circuitry. (A) (Left) CRC model for H1 human embryonic stem cells. The role of each TF in ESC pluripotency and self-renewal is listed in Table 1. (Right) H1 hESC extended regulatory circuit. Examples of SE-assigned genes that are predicted to be bound by each of the TFs in the CRC. The role of these factors in ESC pluripotency and self-renewal is listed in Supplemental Table S5. (B) ChIP-seq data for H3K27ac, POU5F1, SOX2, and NANOG showing binding of the TFs to each of the SEs of the SE-assigned TFs in the hESC CRC. SE genomic locations are depicted by red lines *top* of the tracks. (C) Pie charts showing the percentages of SE-assigned genes (*top* row) or all expressed genes (*bottom* row) whose regulatory sequences are predicted to be bound by increasing numbers of hESC candidate core TFs. (D) Diagram showing putative transcriptional regulation of miR-371a on SOX2 expression in hESCs.

Table 1. Role of hESC candidate core TFs in ESC identity and in the regulation of other candidate core TF expression

TF	Role in ESC identity	Refs.	Regulation of other core TFs	Refs.
POU5F1	Required for ESC pluripotent state. Can be used to reprogram fibroblasts into iPSCs.	Nichols et al. 1998; Niwa et al. 2000; Takahashi and Yamanaka 2006; Yu et al. 2007	Binds to the super-enhancers associated with <i>POU5F1</i> , <i>SOX2</i> and <i>NANOG</i> in H1 ESCs and activates their expression.	Tomioka et al. 2002; Catena et al. 2004; Boyer et al. 2005; Chew et al. 2005; Kuroda et al. 2005; Okumura-Nakanishi et al. 2005; Loh et al. 2006; Kunarso et al. 2010; Hawkins et al. 2011
SOX2	Required for ESC pluripotent state. Can be used to reprogram fibroblasts into iPSCs.	Avilion et al. 2003; Takahashi and Yamanaka 2006; Masui et al. 2007; Yu et al. 2007	Binds to the super-enhancers associated with <i>POU5F1</i> , <i>SOX2</i> and <i>NANOG</i> in H1 ESCs and activates their expression.	Tomioka et al. 2002; Boyer et al. 2005; Chew et al. 2005; Kuroda et al. 2005; Okumura-Nakanishi et al. 2005; Rodda et al. 2005; Loh et al. 2006; Kunarso et al. 2010; Hawkins et al. 2011
NANOG	Required for ESC pluripotent state. Can be used to reprogram fibroblasts into iPSCs.	Chambers et al. 2003; Mitsui et al. 2003; Yu et al. 2007; Silva et al. 2009; Theunissen et al. 2011	Binds to the super-enhancers associated with <i>POU5F1</i> , <i>SOX2</i> and <i>NANOG</i> in H1 ESCs and activates their expression.	Boyer et al. 2005; Loh et al. 2006; Kunarso et al. 2010; Hawkins et al. 2011; Navarro et al. 2012
FOXO1	Required for maintenance of pluripotency in hESCs.	Zhang et al. 2011	Binds to <i>POU5F1</i> and <i>SOX2</i> in hESCs and activates their expression. Its associated super-enhancer is bound by <i>POU5F1</i> , <i>SOX2</i> and <i>NANOG</i> in H1 hESCs.	Kunarso et al. 2010; Hawkins et al. 2011; Zhang et al. 2011
ZIC3	Required for maintenance of pluripotency in mESCs. Contributes to reprogram fibroblasts into iPSCs.	Lim et al. 2007; Declercq et al. 2013	Binds to <i>Nanog</i> and activates its expression in mESC. Its expression is directly regulated by <i>POU5F1</i> , <i>SOX2</i> and <i>NANOG</i> in mESCs. Its super-enhancer is bound by <i>POU5F1</i> , <i>SOX2</i> and <i>NANOG</i> in H1 hESCs.	Lim et al. 2007; Kunarso et al. 2010; Hawkins et al. 2011; Declercq et al. 2013
NR5A1	Can influence ESC pluripotent state.	Guo and Smith 2010	Binds to <i>POU5F1</i> and regulates its expression. Its super-enhancer is bound by <i>POU5F1</i> , <i>SOX2</i> and <i>NANOG</i> in H1 hESCs.	Barnea and Bergman 2000; Yang et al. 2007; Guo and Smith 2010; Kunarso et al. 2010; Hawkins et al. 2011
RARG	Accelerates reprogramming of mouse embryonic fibroblasts to iPSCs.	Wang et al. 2011	Its associated super-enhancer is bound by <i>POU5F1</i> in H1 hESCs.	Kunarso et al. 2010; Hawkins et al. 2011
MYB	Involved in establishing or maintaining self-renewing populations of hematopoietic cells.	White and Weston 2000; Lieu and Reddy 2009; Cheasley et al. 2011; Zuber et al. 2011	Binds regions near the <i>NANOG</i> gene. Its super-enhancer is bound by <i>POU5F1</i> , <i>SOX2</i> and <i>NANOG</i> in H1 hESCs.	Kunarso et al. 2010; Hawkins et al. 2011; Quintana et al. 2011
RORA	Involved in self-renewal and multi-lineages potential of human hematopoietic cells.	Doulatov et al. 2013	Binds to <i>POU5F1</i> and regulates its expression. Its super-enhancer is bound by <i>POU5F1</i> , <i>SOX2</i> and <i>NANOG</i> in H1 hESCs.	Kunarso et al. 2010; Hawkins et al. 2011
SOX21	Regulates pluripotency in intestinal stem cells. Its expression is influenced by <i>SOX2</i> .	Kuzmichev et al. 2012	Its associated super-enhancer is bound by <i>POU5F1</i> , <i>SOX2</i> and <i>NANOG</i> in H1 hESCs.	Kunarso et al. 2010; Hawkins et al. 2011

In ESCs, loss of cell identity can be assayed by measuring *POU5F1* protein levels, where reduced levels are associated with loss of pluripotency, and by counting cell nuclei, where reduced numbers can reflect loss of self-renewal (Chia et al. 2010; Kagey et al. 2010). To test whether the candidate core TFs play roles in control of ESC identity, we analyzed *POU5F1* expression changes and cell nuclei number changes after depletion of each of these TFs using data from a genome-wide siRNA screen in H1 hESCs (Chia et al. 2010). These data confirm that the candidate core TFs contribute to pluripotency and/or survival and proliferation of hESCs (Supplemental Fig. S2A). Gene-set enrichment analysis (GSEA) of the set of candidate core TFs shows these factors are encoded by genes that are among those whose knock-down most impacts *POU5F1* expression and cell nuclei count (Supplemental Fig. S2B,C). These functional assays in H1 hESCs thus provide supporting evidence for a functional role of the candidate core TFs in control of hESC identity.

Extended hESC regulatory circuitry

POU5F1, *SOX2*, and *NANOG* contribute to the formation of SEs at hundreds of active ESC genes that play prominent roles in cell identity (Whyte et al. 2013), suggesting that a simple extended model of regulatory information can be constructed to include these additional SE-assigned genes downstream from the core TFs. We identified the SE-assigned genes whose enhancers and promoters are predicted to be bound by the candidate core TFs in order to construct a model of extended hESC regulatory circuitry (Fig. 2A, right panel). Analysis shows the regulatory sequences of the SE-assigned genes are predicted to be bound by a greater number of candidate core TFs than the regulatory sequences of all expressed genes (Fig. 2C). Sixty-eight percent of the SE-assigned genes are predicted to be bound by each of the core TFs. Experimental evidence (Kunarso et al. 2010) shows that *POU5F1* contributes to the regulation of at least 30% (z -test P -value $< 2.2 \times 10^{-16}$) of

these downstream SE-assigned target genes (Supplemental Table S4). Thus, in the model of extended hESC regulatory circuitry, the core TFs co-occupy and likely regulate the expression of a large portion of SE-assigned genes.

The model of extended hESC regulatory circuitry contains many genes that are known to play prominent roles in ESC biology (Young 2011). These include the TFs PRDM14, SALL4, and ZNF281, the chromatin regulators DNMT3B, JARID2, and SETDB1, and the miRNA miR-371a, all of which have established roles in pluripotency, self-renewal, or differentiation (detailed functions and associated references in Supplemental Table S5). Among the SE-assigned genes, some transcriptional regulators may create feedforward or feedback loops of regulation with the genes in the extended CRC to modulate the direct effect of core TFs. For example, miR-371a, the human homolog of miR-290 which is essential for mESC survival (Medeiros et al. 2011), may fine-tune *SOX2* expression in hESCs (Fig. 2D). *SOX2* is identified as a highly probable target of miR-371a by multiple miRNA target predictor algorithms, including TargetScan (Lewis et al. 2005), miRDB (Wong and Wang 2015), and PITA (Kertesz et al. 2007) (Supplemental Table S6), and recent functional assays in human cancer cells (Li et al. 2015) support a role for miR-371a in direct regulation of *SOX2* expression. We therefore suggest that the ESC gene expression program is controlled by a CRC consisting of ten key TFs that (1) bind the SEs of their own genes and regulate their own expression, and (2) co-bind the SEs of many other genes important for ESC identity and regulate their expression.

CRC and extended regulatory circuitry for many cell types

We next developed models of CRC and extended regulatory circuitry for each of 75 human cell and tissue types (Fig. 3; Supplemental Table S3). The predicted CRCs contain key transcriptional regulators of cell identity that have been previously identified (Supplemental Table S7). This includes, for example, *TBX5* in the heart (left ventricle) CRC (Ieda et al. 2010; Song et al. 2012; Nam et al. 2014), *PDX1* in the pancreas CRC (Jonsson et al. 1994; Horb et al. 2003; Zhou et al. 2008), and *SOX2* in the brain (hippocampus middle) CRC (Graham et al. 2003; Ferri 2004; Sisodiya et al. 2006; Lujan et al. 2012). They also contain well-characterized proto-oncogenes of cancer subtypes represented by cancer cell lines, such as *ESR1* and *GATA3* in MCF-7 breast cancer cells (Usary et al. 2004; Holst et al. 2007) and *TCF7L2* and *SMAD3* in HCT-116 colon cancer cells (Supplemental Fig. S3; Zhu et al. 1998; Tuupainen et al. 2009). Importantly, our approach recapitulates the oncogenic circuitry that had been previously identified in T-cell acute lymphoblastic leukemia (T-ALL) Jurkat cells (Sanda et al. 2012; Mansour et al. 2014), as one of the CRCs for Jurkat cells contains the four oncogenic TFs—*GATA3*, *MYB*, *RUNX1*, and *TAL1*—previously characterized as core TFs in this cell line (Fig. 4A). Together, these data indicate that the CRC models capture much existing knowledge of TFs that play key roles in control of cell identity across diverse cell and tissue types.

We used experimental data to test the accuracy of our predictions in newly identified CRCs. The binding of the core TFs to the super-enhancer sequences of the other predicted TFs in the core is supported by ChIP-seq data for core TFs in T-ALL Jurkat cells (Fig. 4B). Available ChIP-seq data for TFs in the CRCs for other cell types were also analyzed and lend functional support for the predicted binding interactions in the CRCs (Supplemental Fig. S3). To test the mutual regulation of the TFs in the core, we investigated the effects of shRNA depletion of *MYB*, *RUNX1*, *TAL1*, and

GATA3 on expression of candidate core TF-encoding genes in T-ALL Jurkat cells (Fig. 4C). Analysis of the data shows that when a core TF is depleted, the expression of the TFs in the core is significantly down-regulated compared to the set of TFs considered expressed in the cell. This observation is in agreement with a direct effect of the core TFs on the expression of the other TFs in the core.

The candidate core TFs identified across a wide range of cell types show features of core TFs that have previously been described (Lee and Young 2013). Analysis of the candidate core TFs across samples shows that these are cell-type-specific or lineage-specific: 34% of the core TFs identified across cell types are predicted to be core TFs in only one cell type, and 77% are predicted to be core TFs in less than five cell types (Fig. 5A). DNA-binding domain structures can provide insight on the functional roles of TFs (Vaquerizas et al. 2009), so we compared the frequency of different DNA-binding domains in candidate core TFs to those in ubiquitously expressed housekeeping TFs. Compared to housekeeping TFs, candidate core TFs are depleted in the most common type of TFs—zinc finger domain-containing TFs—and enriched in various classes of TFs that have been associated with developmental processes, such as homeodomain-containing TFs (Fig. 5B). Analysis of expression data shows that candidate core TFs exhibit higher transcript levels when compared to the full set of TFs considered expressed in the cell (Fig. 5C). The candidate core TFs are thus cell-type- or lineage-specific, enriched for functional association with development processes, and show a relatively high level of expression compared to other TFs expressed in the cell.

Analyzing CRCs across cell types, we identified features of CRCs that should help guide further experiments to better understand the transcriptional pathways involved in development and disease. We observed that a substantial fraction of candidate core TFs is expressed in multiple cell types, typically within a lineage. This feature of shared core TFs within lineages is evident through hierarchical clustering of candidate core TFs across all data sets (Fig. 6A). It suggests that specific combinations of TFs may be required to control complementary aspects of cell identity and that circuitries may be rewired through ectopic expression of a few TFs between similar cell types. We also found that, compared to other TFs, candidate core TFs are found significantly more often in the set of genes associated with diseases or traits via genome-wide association studies (GWAS), which suggests their involvement in cell identity and disease development (Fig. 6B; Supplemental Fig. S4). Previous studies have shown that disease-associated SNPs are enriched in SEs (Hnisz et al. 2013; Parker et al. 2013), and there are multiple examples of noncoding disease-associated SNPs overlapping the super-enhancers associated with TFs in the CRC (Supplemental Fig. S4).

We generated models of extended regulatory circuitry for 75 cell and tissue types using the same process described above for the hESC extended regulatory circuitry (Fig. 3). The features of these extended circuitries are consistent with those observed for hESCs. On average, across samples, 73% of the SE-assigned genes are predicted to be co-occupied by each of the candidate core TFs (Fig. 6C), and these SE-assigned target genes of the CRC play prominent roles in specific cell identities (Fig. 3).

Discussion

There have been tremendous advances in our understanding of the general mechanisms involved in control of gene transcription (Roeder 2005; Rajapakse et al. 2009; Bonasio et al. 2010; Conaway and Conaway 2011; Novershtern et al. 2011; Adelman




Figure 3. Core and extended regulatory circuitry for multiple cells and tissue types. Core and extended circuitry for (A) brain (hippocampus middle), (B) adipocytes (adipose nuclei), (C) heart (left ventricle), and (D) pancreas. The number of SE-assigned genes predicted to be co-occupied by each of the candidate core TFs and 30 examples of those are displayed on the *right* part of the maps.




Figure 4. Experimental validation for T-ALL Jurkat cell circuitry. (A) Core regulatory circuit containing GATA3, MYB, RUNX1, and TAL1 for T-ALL Jurkat cells. (B) ChIP-seq data for H3K27ac, MYB, RUNX1, TAL1, and GATA3 showing binding of the TF to each of the SEs in the T-ALL Jurkat cell core circuit. SE genomic locations are depicted by red lines on top of the tracks. (C) Boxplots showing fold change (FC) in expression for Jurkat cells transfected with the indicated shRNAs vs. control shRNAs, for either the set of candidate core TFs displayed in A (red) or the full set of TFs considered expressed in Jurkat cells (blue). P-values quantifying the difference between the two sets were calculated using a Wilcoxon test.

and Lis 2012; Peter et al. 2012; Spitz and Furlong 2012; Zhou et al. 2012; de Wit et al. 2013; Gifford et al. 2013; Kumar et al. 2014; Ziller et al. 2014; Dixon et al. 2015; Tsankov et al. 2015), but the pathways by which a small set of core TFs control gene expression programs have yet to be mapped in most cells. We describe here models of core transcriptional regulatory circuitry for 75 human cell and tissue types. These models show significant percentages of overlap between the TF-TF binding interactions we predict in the CRCs and the TF-TF interactions identified in previous high-throughput analyses, for similar cell types (Supplemental Table S8; Neph et al. 2012). The CRC models we provide include known core TFs and reprogramming TFs that have been previously identified in a few cell types but add a large list of candidate cell identity regulators. These include ubiquitous and signaling TFs that should work together with the minimal set of TFs required to reprogram

cells from one state to another, to establish and maintain cellular identity. These models provide the foundation for future studies of the transcriptional pathways that control cell identity in these diverse cell types of the human body.

Key target genes of the CRC were identified in a first step toward understanding how the information flows from the core TFs to all expressed genes. Across all cell and tissue types, the candidate core TFs were predicted to preferentially co-occupy SE-assigned genes, compared to all expressed genes. As SE-assigned genes are typically key for cell identity (Chapuy et al. 2013; Hnisz et al. 2013; Parker et al. 2013; Whyte et al. 2013; Loft et al. 2015), this shows that the concerted action of candidate core TFs may be preferentially targeted to those key cell identity genes. This led us to envision a model whereby the core TFs promote hallmarks of cell identities through co-binding the SEs of their own genes and




Figure 5. Features of candidate core TFs. (A) Percentages of TFs identified as candidate core TFs in a given number of cell or tissue types. The number of cell or tissue types in which a TF is identified as a candidate core TF is displayed with boxes on the right. A representative sample of each cell and tissue type is used when multiple samples from the same cell or tissue type are present in the data set. (B) DNA-binding domains that are significantly differentially represented in the set of candidate core TFs and housekeeping TFs. (C) Transcript levels for the set of candidate core TFs and for the full set of TFs considered expressed in each sample. *P*-values quantifying the difference between the two sets were calculated using a Wilcoxon test.

regulating their own expression, and co-binding the SEs of many other genes important for cell identity and regulating their expression. The maps of CRC were thus extended to include the SE-assigned target genes of the CRC. These maps of extended regulatory circuitry are founding models for the description of more comprehensive networks that describe additional levels of regulation that should include signaling pathways, as super-enhancers serve as integrating platforms for signaling (Siersbæk et al. 2014b; Hnisz et al. 2015).

The approach presented here constitutes a first attempt to map CRCs in a wide range of cell types and harbors several limitations that should be considered when using the data. The analyses were restricted to TFs that were assigned to a SE in the data set and for which DNA-binding motifs are available. The CRC models also rely on data derived from cell lines, which do not necessarily reflect the state of cells in their normal niche, or from biopsies, which include mixed populations of cell types. Another consideration is the challenge of comprehensive experimental validation of the circuits, which would in principle require knock-out of individual core TFs and perhaps combinations of these TFs. Ongoing efforts to characterize DNA-binding motifs for TFs (Jolma et al. 2013; Mathelier et al. 2014; Hume et al. 2015), taking into account the influence of their TF partners, and the role of coactivators and chromatin regulators on their binding to regulatory sequences (Chen et al. 2008; Yan et al. 2013; Siersbæk et al. 2014a; Schmidt et al. 2015), and further experimental testing should help refine the description of the CRC models we provide here.

CRC models should provide guidance for reprogramming studies and may prove valuable for better understanding transcriptional dysregulation in disease. Candidate core TFs are enriched in the genes associated with multiple diseases or traits through GWAS, supporting their role in disease development. Furthermore, SEs are hotspots of noncoding disease-associated sequence variants (Maurano et al. 2012; Hnisz et al. 2013; Parker et al. 2013; Corradin et al. 2014; Farh et al. 2015). Some of these variants may modify the binding sites for core TFs, providing a mechanism for disease-associated transcriptional misregulation. This is the case, for example, of TFs we predict in CRCs such as TAL1 in T cells, TBX5 in cardiac cells, TCF7L2 in colorectal cancer cells, and ESR1 and GATA3 in breast cancer cells (Tuupanen et al. 2009; Cowper-Salari et al. 2012; Sur et al. 2012; Van den Boogaard et al. 2012; Bauer et al. 2013; French et al. 2013). Extended regulatory circuits integrating candidate core TFs and their SE-assigned target genes for many human cell types may thus help better understand disease-associated genetic variation, leading someday to circuitry-directed therapeutic interventions.

Methods

ChIP-seq data

H3K27ac ChIP-seq data were either downloaded from GEO (accession numbers in Supplemental Table S1) or generously shared by the NIH Roadmap Epigenome project (Bernstein et al. 2010). ChIP-seq data for H3K27ac (Kwiatkowski et al. 2014), MYB (Mansour et al. 2014) and TAL1 (Palii et al. 2011) in Jurkat cells and for POU5F1 (Kunarso et al. 2010), SOX2 (Hawkins et al. 2011), and NANOG (Kunarso et al. 2010) in H1 hESCs were downloaded from GEO. ChIP-seq data for CREB1, EBF1, ELF1, ETS1, PAX5, and POU2F2 in GM12878 lymphoblastoid B cells, for TCF7L2 in HCT-116 colon cancer cell line, and for ESR1 in T-47D breast cancer cell line were downloaded from ENCODE (Gertz et al. 2013).




Figure 6. Properties of CRCs of multiple human cell and tissue types. (A) CRCs cluster according to cell type similarity. Hierarchical clustering of candidate core TFs for 80 human samples. The matrix of correlation based on Pearson coefficients identifies specific clusters for hematopoietic stem cells (HSC), blood cancer cells, blood cells, epithelial normal and cancer cells, cardio-pulmonary system cells, upper gastrointestinal system, and brain cells. Correlation values range from -1 to 1 and are colored from blue to red according to the color scale. (B) Radar plot showing the enrichment of candidate core TFs, compared to noncore TFs, in GWAS list of genes for multiple diseases or traits. P -values were calculated using a z -test, and $1/P$ -values are plotted for the diseases or traits that showed an enrichment P -value $< 5 \times 10^{-2}$ of candidate core TFs. (C) Pie charts showing the average percentages for all samples of SE-assigned genes (*top row*) or of all expressed genes (*bottom row*) whose regulatory sequences are predicted to be co-occupied by more than half or by all the TFs in the CRC.

CRC mapper

The algorithm we developed to identify core regulatory circuitry uses as input H3K27ac ChIP-seq reads aligned to the human genome, together with the ChIP-seq peaks identified by MACS (Zhang et al. 2008) and the enhancer table output from ROSE (https://bitbucket.org/young_computation/rose) (Lovén et al. 2013). SEs identified with ROSE are assigned to the closest transcript predicted to be expressed. For each SE-assigned TF, a motif analysis is carried out on the SE constituent sequences assigned to that TF using FIMO (Find Individual Motif Occurrences) from the MEME (Multiple Em for Motif Elicitation) suite (Grant et al. 2011). A database of DNA sequence motifs for 695 TFs was compiled from the TRANSFAC database of motifs (Matys et al. 2006), and from the MEME suite (January 23rd 2014 update), for the following collections: JASPAR CORE 2014 vertebrates (Mathelier et al. 2014), Jolma 2013 (Jolma et al. 2013), Homeodomains (Berger et al. 2008), mouse UniPROBE (Robasky and Bulyk 2011), and mouse and human ETS factors (Wei et al. 2010). For the motif search, the search space in SEs is restricted to extended SE constituents, as these are the regions that capture most of the TF binding in SEs (Fig. 1C). SE constituent DNA sequences are extracted, extended on each side (500 bp by default), and used for motif search with FIMO with a P -value threshold of 1×10^{-4} . SE-assigned TFs whose set of constituents contains at least three DNA sequence motif instances for their own protein products are defined as auto-regulated TFs. From the set of auto-regulated TFs, the TFs predicted to bind to the SEs of other auto-regulated TFs, using the same criteria as described above, are identified. All possible fully interconnected auto-regulatory loops of TFs are then constructed through recursive identification. When multiple possibilities of fully interconnected auto-regulatory loops are found, the most representative fully interconnected auto-regulatory loop of TFs is selected as the model of CRC. This loop is defined as the loop containing the TFs that occur the most frequently across all possible loops. See Supplemental Methods for details.

Data access

ChIP-seq data for RUNX1 and GATA3 in Jurkat cells from this study have been submitted to the NCBI Gene Expression Omnibus (GEO; <https://www.ncbi.nlm.nih.gov/geo/>) under accession number

GSE76181. The CRC Mapper program is implemented in Python. It can be found in the Supplemental Material and is freely available for download at https://bitbucket.org/young_computation/crcmapper.

Competing interest statement

R.A.Y. and J.E.B. are founders of Syros Pharmaceuticals.

Acknowledgments

We thank members of the Young lab, especially Ana D'Alessio, Zi Peng Fan, and Jurian Schuijers for helpful discussions. This work was supported by the Foundation for the National Institutes of Health grant HG002668 (R.A.Y.). A.J.F. was funded by a National Science Foundation graduate fellowship, and B.J.A. is the Hope Funds for Cancer Research Grillo-Marxuach Family Fellow.

References

- Adelman K, Lis JT. 2012. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. *Nat Rev Genet* **13**: 720–731.
- Alon U. 2007. Network motifs: theory and experimental approaches. *Nat Rev Genet* **8**: 450–461.
- Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. 2003. Multipotent cell lineages in early mouse development depend on SOX2 function. *Genes Dev* **17**: 126–140.
- Bar-Joseph Z, Gerber GK, Lee TI, Rinaldi NJ, Yoo JY, Robert F, Gordon DB, Fraenkel E, Jaakkola TS, Young RA, et al. 2003. Computational discovery of gene modules and regulatory networks. *Nat Biotechnol* **21**: 1337–1342.
- Barnea E, Bergman Y. 2000. Synergy of SF1 and RAR in activation of Oct-3/4 promoter. *J Biol Chem* **275**: 6608–6619.
- Bauer DE, Kamran SC, Lessard S, Xu J, Fujiwara Y, Lin C, Shao Z, Canver MC, Smith EC, Pinello L, et al. 2013. An erythroid enhancer of *BCL11A* subject to genetic variation determines fetal hemoglobin level. *Science* **342**: 253–257.
- Berger MF, Badis G, Gehrke AR, Talukder S, Philippakis AA, Peña-Castillo L, Alleyne TM, Mnaimneh S, Botvinnik OB, Chan ET, et al. 2008. Variation in homeodomain DNA binding revealed by high-resolution analysis of sequence preferences. *Cell* **133**: 1266–1276.
- Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, Kellis M, Marra MA, Beaudet AL, Ecker JR, et al. 2010. The NIH Roadmap Epigenomics Mapping Consortium. *Nat Biotechnol* **28**: 1045–1048.
- Bonasio R, Tu S, Reinberg D. 2010. Molecular signals of epigenetic states. *Science* **330**: 612–616.
- Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, et al. 2005. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* **122**: 947–956.
- Buganim Y, Faddah DA, Jaenisch R. 2013. Mechanisms and models of somatic cell reprogramming. *Nat Rev Genet* **14**: 427–439.
- Catena R, Tiveron C, Ronchi A, Porta S, Ferri A, Tatangelo L, Cavallaro M, Favaro R, Ottolenghi S, Reinbold R, et al. 2004. Conserved POU binding DNA sites in the Sox2 upstream enhancer regulate gene expression in embryonic and neural stem cells. *J Biol Chem* **279**: 41846–41857.
- Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. 2003. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell* **113**: 643–655.
- Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MGM, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, et al. 2013. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. *Cancer Cell* **24**: 777–790.
- Cheasley D, Pereira L, Lightowler S, Vincan E, Malaterre J, Ramsay RG. 2011. Myb controls intestinal stem cell genes and self-renewal. *Stem Cells* **29**: 2042–2050.
- Chen X, Vega VB, Ng H-H. 2008. Transcriptional regulatory networks in embryonic stem cells. *Cold Spring Harb Symp Quant Biol* **73**: 203–209.
- Chew J-L, Loh Y-H, Zhang W, Chen X, Tam W-L, Yeap L-S, Li P, Ang Y-S, Lim B, Robson P, et al. 2005. Reciprocal transcriptional regulation of *Pou5f1* and *Sox2* via the Oct4/Sox2 complex in embryonic stem cells. *Mol Cell Biol* **25**: 6031–6046.
- Chia N-Y, Chan Y-S, Feng B, Lu X, Orlov YL, Moreau D, Kumar P, Yang L, Jiang J, Lau M-S, et al. 2010. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. *Nature* **468**: 316–320.
- Conaway RC, Conaway JW. 2011. Origins and activity of the Mediator complex. *Semin Cell Dev Biol* **22**: 729–734.
- Corradin O, Saiakhova A, Akhtar-Zaidi B, Myeroff L, Willis J, Cowper-Salari R, Lupien M, Markowitz S, Scacheri PC. 2014. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. *Genome Res* **24**: 1–13.
- Cowper-Salari R, Zhang X, Wright JB, Bailey SD, Cole MD, Eeckhoutte J, Moore JH, Lupien M. 2012. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. *Nat Genet* **44**: 1191–1198.
- Davidson EH. 2010. Emerging properties of animal gene regulatory networks. *Nature* **468**: 911–920.
- de Wit E, Bouwman BAM, Zhu Y, Klous P, Splinter E, Verstegen MJAM, Krijger PHL, Festuccia N, Nora EP, Welling M, et al. 2013. The pluripotent genome in three dimensions is shaped around pluripotency factors. *Nature* **501**: 227–231.
- Declercq J, Sheshadri P, Verfaillie CM, Kumar A. 2013. Zic3 enhances the generation of mouse induced pluripotent stem cells. *Stem Cells Dev* **22**: 2017–2025.
- Dixon JR, Jung I, Selvaraj S, Shen Y, Antosiewicz-Bourget JE, Lee AY, Ye Z, Kim A, Rajagopal N, Xie W, et al. 2015. Chromatin architecture reorganization during stem cell differentiation. *Nature* **518**: 331–336.
- Doulatov S, Vo LT, Chou SS, Kim PG, Arora N, Li H, Hadland BK, Bernstein ID, Collins JJ, Zon LI, et al. 2013. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. *Cell Stem Cell* **13**: 459–470.
- Downen JM, Fan ZP, Hnisz D, Ren G, Abraham BJ, Zhang LN, Weintraub AS, Schuijers J, Lee TI, Zhao K, et al. 2014. Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. *Cell* **159**: 374–387.
- Dutkowskij J, Kramer M, Surma MA, Balakrishnan R, Cherry JM, Krogan NJ, Ideker T. 2013. A gene ontology inferred from molecular networks. *Nat Biotechnol* **31**: 38–45.
- Farh KK-H, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, Shores N, Whitton H, Ryan RJH, Shishkin AA, et al. 2015. Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature* **518**: 337–343.
- Ferri ALM. 2004. Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. *Development* **131**: 3805–3819.
- French JD, Ghossein M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, Khan S, Maranian MJ, O'Reilly M, Hillman KM, et al. 2013. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *Am J Hum Genet* **92**: 489–503.
- Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan K-K, Cheng C, Mu XJ, Khurana E, Rozowsky J, Alexander R, et al. 2012. Architecture of the human regulatory network derived from ENCODE data. *Nature* **489**: 91–100.
- Gertz J, Savic D, Varley KE, Partridge EC, Safi A, Jain P, Cooper GM, Reddy TE, Crawford GE, Myers RM. 2013. Distinct properties of cell-type-specific and shared transcription factor binding sites. *Mol Cell* **52**: 25–36.
- Gifford CA, Ziller MJ, Gu H, Trapnell C, Donaghey J, Tsankov A, Shalek AK, Kelley DR, Shishkin AA, Issner R, et al. 2013. Transcriptional and epigenetic dynamics during specification of human embryonic stem cells. *Cell* **153**: 1149–1163.
- Graf T, Enver T. 2009. Forcing cells to change lineages. *Nature* **462**: 587–594.
- Graham V, Khudyakov J, Ellis P, Pevny L. 2003. SOX2 functions to maintain neural progenitor identity. *Neuron* **39**: 749–765.
- Grant CE, Bailey TL, Noble WS. 2011. FIMO: scanning for occurrences of a given motif. *Bioinformatics* **27**: 1017–1018.
- Guo G, Smith A. 2010. A genome-wide screen in EpiSCs identifies Nr5a nuclear receptors as potent inducers of ground state pluripotency. *Development* **137**: 3185–3192.
- Hawkins RD, Hon GC, Yang C, Antosiewicz-Bourget JE, Lee LK, Ngo Q-M, Klugman S, Ching KA, Edsall LE, Ye Z, et al. 2011. Dynamic chromatin states in human ES cells reveal potential regulatory sequences and genes involved in pluripotency. *Cell Res* **21**: 1393–1409.
- Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. 2013. Super-enhancers in the control of cell identity and disease. *Cell* **155**: 934–947.
- Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, Bradner JE, Young RA. 2015. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. *Mol Cell* **58**: 362–370.
- Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F, et al. 2007. Estrogen receptor α (ESR1) gene amplification is frequent in breast cancer. *Nat Genet* **39**: 655–660.
- Horb ME, Shen CN, Tosh D, Slack JMW. 2003. Experimental conversion of liver to pancreas. *Curr Biol* **13**: 105–115.
- Hume MA, Barrera LA, Gisselbrecht SS, Bulyk ML. 2015. UniPROBE, update 2015: new tools and content for the online database of protein-binding

- microarray data on protein–DNA interactions. *Nucleic Acids Res* **43**: D117–D122.
- Ieda M, Fu J-D, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D. 2010. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. *Cell* **142**: 375–386.
- Jaenisch R, Young R. 2008. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. *Cell* **132**: 567–582.
- Jolma A, Yan J, Whittington T, Toivonen J, Nitta KR, Rastas P, Morgunova E, Enge M, Taipale M, Wei G, et al. 2013. DNA-binding specificities of human transcription factors. *Cell* **152**: 327–339.
- Jonsson J, Carlsson L, Edlund T, Edlund H. 1994. Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature* **371**: 606–609.
- Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, Ebmeier CC, Goossens J, Rahl PB, Levine SS, et al. 2010. Mediator and cohesin connect gene expression and chromatin architecture. *Nature* **467**: 430–435.
- Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. 2012. KEGG for integration and interpretation of large-scale molecular data sets. *Nucleic Acids Res* **40**: D109–D114.
- Kemmerer P, Sameith K, van de Pasch LAL, Benschop JJ, Lenstra TL, Margaritis T, O'Duibhir E, Apweiler E, van Wageningen S, Ko CW, et al. 2014. Large-scale genetic perturbations reveal regulatory networks and an abundance of gene-specific repressors. *Cell* **157**: 740–752.
- Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. 2007. The role of site accessibility in microRNA target recognition. *Nat Genet* **39**: 1278–1284.
- Krebs HA. 1940. The citric acid cycle and the Szent-Györgyi cycle in pigeon breast muscle. *Biochem J* **34**: 775–779.
- Kumar RM, Cahan P, Shalek AK, Satija R, Jay DaleyKeyser A, Li H, Zhang J, Pardee K, Gennert D, Trombetta JJ, et al. 2014. Deconstructing transcriptional heterogeneity in pluripotent stem cells. *Nature* **516**: 56–61.
- Kunarto G, Chia N-Y, Jeyakani J, Hwang C, Lu X, Chan Y-S, Ng H-H, Bourque G. 2010. Transposable elements have rewired the core regulatory network of human embryonic stem cells. *Nat Genet* **42**: 631–634.
- Kuroda T, Tada M, Kubota H, Kimura H, Hatano S, Suemori H, Nakatsuji N, Tada T. 2005. Octamer and Sox elements are required for transcriptional *cis* regulation of *Nanog* gene expression. *Mol Cell Biol* **25**: 2475–2485.
- Kuzmichev AN, Kim S-K, D'Alessio AC, Chenoweth JG, Wittko IM, Campanati L, McKay RD. 2012. *Sox2* acts through *Sox21* to regulate transcription in pluripotent and differentiated cells. *Curr Biol* **22**: 1705–1710.
- Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, et al. 2014. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. *Nature* **511**: 616–620.
- Lee TI, Young RA. 2013. Transcriptional regulation and its misregulation in disease. *Cell* **152**: 1237–1251.
- Lee TI, Rinaldi NJ, Robert F, Odom DT, Bar-Joseph Z, Gerber GK, Hannett NM, Harbison CT, Thompson CM, Simon I, et al. 2002. Transcriptional regulatory networks in *Saccharomyces cerevisiae*. *Science* **298**: 799–804.
- Lefebvre C, Rajbhandari P, Alvarez MJ, Bandaru P, Lim WK, Sato M, Wang K, Sumazin P, Kustagi M, Bisikirska BC, et al. 2010. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. *Mol Syst Biol* **6**: 377.
- Levine M, Cattoglio C, Tjian R. 2014. Looping back to leap forward: transcription enters a new era. *Cell* **157**: 13–25.
- Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* **120**: 15–20.
- Li Y, Lv Z, He G, Wang J, Zhang X, Lu G, Ren X, Wang F, Zhu X, Ding Y, et al. 2015. The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer. *Oncotarget* **6**: 9099–9112.
- Lieu YK, Reddy EP. 2009. Conditional *c-myc* knockout in adult hematopoietic stem cells leads to loss of self-renewal due to impaired proliferation and accelerated differentiation. *Proc Natl Acad Sci* **106**: 21689–21694.
- Lim LS, Loh Y-H, Zhang W, Li Y, Chen X, Wang Y, Bakre M, Ng H-H, Stanton LW. 2007. *Zic3* is required for maintenance of pluripotency in embryonic stem cells. *Mol Biol Cell* **18**: 1348–1358.
- Loft A, Forss I, Siersbæk MS, Schmidt SF, Larsen A-SB, Madsen JGS, Pisani DF, Nielsen R, Aagaard MM, Mathison A, et al. 2015. Browning of human adipocytes requires KLF11 and reprogramming of PPAR γ superenhancers. *Genes Dev* **29**: 7–22.
- Loh Y-H, Wu Q, Chew J-L, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, et al. 2006. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. *Nat Genet* **38**: 431–440.
- Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. 2013. Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell* **153**: 320–334.
- Lujan E, Chanda S, Ahlenius H, Südhof TC, Wernig M. 2012. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. *Proc Natl Acad Sci* **109**: 2527–2532.
- Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, et al. 2014. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. *Science* **346**: 1373–1377.
- Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, Okochi H, Okuda A, Matoba R, Sharov AA, et al. 2007. Pluripotency governed by *Sox2* via regulation of *Oct3/4* expression in mouse embryonic stem cells. *Nat Cell Biol* **9**: 625–635.
- Mathelier A, Zhao X, Zhang AW, Parcy F, Worsley-Hunt R, Arenillas DJ, Buchman S, Chen C, Chou A, Ienasescu H, et al. 2014. JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. *Nucleic Acids Res* **42**: D142–D147.
- Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter I, Chekmenev D, Krull M, Hornischer K, et al. 2006. TRANSFAC and its module TRANSCOMP: transcriptional gene regulation in eukaryotes. *Nucleic Acids Res* **34**: D108–D110.
- Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, Sandstrom R, Qu H, Brody J, et al. 2012. Systematic localization of common disease-associated variation in regulatory DNA. *Science* **337**: 1190–1195.
- Medeiros LA, Dennis LM, Gill ME, Houbaviiy H, Markoulaki S, Fu D, White AC, Kirak O, Sharp PA, Page DC, et al. 2011. *Mir-290–295* deficiency in mice results in partially penetrant embryonic lethality and germ cell defects. *Proc Natl Acad Sci* **108**: 14163–14168.
- Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. 2003. The homeoprotein *Nanog* is required for maintenance of pluripotency in mouse epiblast and ES cells. *Cell* **113**: 631–642.
- Morris SA, Daley GQ. 2013. A blueprint for engineering cell fate: current technologies to reprogram cell identity. *Cell Res* **23**: 33–48.
- Nam Y-J, Lubczyk C, Bhakta M, Zang T, Fernandez-Perez A, McAnally J, Bassel-Duby R, Olson EN, Munshi NV. 2014. Induction of diverse cardiac cell types by reprogramming fibroblasts with cardiac transcription factors. *Development* **141**: 4267–4278.
- Navarro P, Festuccia N, Colby D, Gagliardi A, Mullin NP, Zhang W, Karwacki-Neisius V, Osorno R, Kelly D, Robertson M, et al. 2012. OCT4/SOX2-independent *Nanog* autorepression modulates heterogeneous *Nanog* gene expression in mouse ES cells. *EMBO J* **31**: 4547–4562.
- Neph S, Stergachis AB, Reynolds A, Sandstrom R, Borenstein E, Stamatoyannopoulos JA. 2012. Circuitry and dynamics of human transcription factor regulatory networks. *Cell* **150**: 1274–1286.
- Nichols J, Zevnik B, Anastasiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Schöler H, Smith A. 1998. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* **95**: 379–391.
- Niwa H, Miyazaki J, Smith AG. 2000. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat Genet* **24**: 372–376.
- Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, McConkey ME, Habib N, Yosef N, Chang CY, Shay T, et al. 2011. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. *Cell* **144**: 296–309.
- Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, et al. 2004. Control of pancreas and liver gene expression by HNF transcription factors. *Science* **303**: 1378–1381.
- Odom DT, Dowell RD, Jacobsen ES, Neklodova L, Rolfe PA, Danford TW, Gifford DK, Fraenkel E, Bell GI, Young RA. 2006. Core transcriptional regulatory circuitry in human hepatocytes. *Mol Syst Biol* **2**: 2006.0017.
- Okumura-Nakanishi S, Saito M, Niwa H, Ishikawa F. 2005. Oct-3/4 and Sox2 regulate *Oct-3/4* gene in embryonic stem cells. *J Biol Chem* **280**: 5307–5317.
- Palii CG, Perez-Iratxeta C, Yao Z, Cao Y, Dai F, Davison J, Atkins H, Allan D, Dilworth FJ, Gentleman R, et al. 2011. Differential genomic targeting of the transcription factor TAL1 in alternate haematopoietic lineages. *EMBO J* **30**: 494–509.
- Parker SCJ, Stitzel ML, Taylor DL, Orozco JM, Erdos MR, Akiyama JA, van Bueren KL, Chines PS, Narisu N, Black BL, et al. 2013. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. *Proc Natl Acad Sci* **110**: 17921–17926.
- Peter IS, Faure E, Davidson EH. 2012. Predictive computation of genomic logic processing functions in embryonic development. *Proc Natl Acad Sci* **109**: 16434–16442.
- Pique-Regi R, Degner JF, Pai AA, Gaffney DJ, Gilad Y, Pritchard JK. 2011. Accurate inference of transcription factor binding from DNA sequence and chromatin accessibility data. *Genome Res* **21**: 447–455.
- Quintana AM, Zhou YE, Pena JJ, O'Rourke JP, Ness SA. 2011. Dramatic repositioning of c-Myb to different promoters during the cell cycle observed by combining cell sorting with chromatin immunoprecipitation. *PLoS One* **6**: e17362.

- Rajapakse I, Perlman MD, Scalzo D, Kooperberg C, Groudine M, Kosak ST. 2009. The emergence of lineage-specific chromosomal topologies from coordinate gene regulation. *Proc Natl Acad Sci* **106**: 6679–6684.
- Robasky K, Bulyk ML. 2011. UniPROBE, update 2011: expanded content and search tools in the online database of protein-binding microarray data on protein–DNA interactions. *Nucleic Acids Res* **39**: D124–D128.
- Rodda DJ, Chew J-L, Lim L-H, Loh Y-H, Wang B, Ng H-H, Robson P. 2005. Transcriptional regulation of *Nanog* by OCT4 and SOX2. *J Biol Chem* **280**: 24731–24737.
- Roeder RG. 2005. Transcriptional regulation and the role of diverse coactivators in animal cells. *FEBS Lett* **579**: 909–915.
- Rolland T, Taşan M, Charlotiaux B, Pevzner SJ, Zhong Q, Sahni N, Yi S, Lemmens I, Fontanillo C, Mosca R, et al. 2014. A proteome-scale map of the human interactome network. *Cell* **159**: 1212–1226.
- Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, et al. 2012. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. *Cancer Cell* **22**: 209–221.
- Schmidt SF, Larsen BD, Loft A, Nielsen R, Madsen JGS, Mandrup S. 2015. Acute TNF-induced repression of cell identity genes is mediated by NFκB-directed redistribution of cofactors from super-enhancers. *Genome Res* **25**: 1281–1294.
- Siersbæk R, Baek S, Rabiee A, Nielsen R, Traynor S, Clark N, Sandelin A, Jensen ON, Sung M-H, Hager GL, et al. 2014a. Molecular architecture of transcription factor hotspots in early adipogenesis. *Cell Rep* **7**: 1434–1442.
- Siersbæk R, Rabiee A, Nielsen R, Sidoli S, Traynor S, Loft A, La Cour Poulsen L, Rogowska-Wrzesinska A, Jensen ON, Mandrup S. 2014b. Transcription factor cooperativity in early adipogenic hotspots and super-enhancers. *Cell Rep* **7**: 1443–1455.
- Silva J, Nichols J, Theunissen TW, Guo G, van Oosten AL, Barrandon O, Wray J, Yamanaka S, Chambers I, Smith A. 2009. *Nanog* is the gateway to the pluripotent ground state. *Cell* **138**: 722–737.
- Sisodiya SM, Ragge NK, Cavalleri GL, Hever A, Lorenz B, Schneider A, Williamson KA, Stevens JM, Free SL, Thompson PJ, et al. 2006. Role of SOX2 mutations in human hippocampal malformations and epilepsy. *Epilepsia* **47**: 534–542.
- Song K, Nam Y-J, Luo X, Qi X, Tan W, Huang GN, Acharya A, Smith CL, Tallquist MD, Neilson EG, et al. 2012. Heart repair by reprogramming non-myocytes with cardiac transcription factors. *Nature* **485**: 599–604.
- Spitz F, Furlong EEM. 2012. Transcription factors: from enhancer binding to developmental control. *Nat Rev Genet* **13**: 613–626.
- Stergachis AB, Neph S, Sandstrom R, Haugen E, Reynolds AP, Zhang M, Byron R, Canfield T, Stelling-Sun S, Lee K, et al. 2014. Conservation of trans-acting circuitry during mammalian regulatory evolution. *Nature* **515**: 365–370.
- Sur IK, Hallikas O, Vähärautio A, Yan J, Turunen M, Enge M, Taipale M, Karhu A, Aaltonen LA, Taipale J. 2012. Mice lacking a *Myc* enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. *Science* **338**: 1360–1363.
- Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126**: 663–676.
- Theunissen TW, van Oosten AL, Castelo-Branco G, Hall J, Smith A, Silva JCR. 2011. *Nanog* overcomes reprogramming barriers and induces pluripotency in minimal conditions. *Curr Biol* **21**: 65–71.
- Tomioka M, Nishimoto M, Miyagi S, Katayanagi T, Fukui N, Niwa H, Muramatsu M, Okuda A. 2002. Identification of Sox-2 regulatory region which is under the control of Oct-3/4–Sox-2 complex. *Nucleic Acids Res* **30**: 3202–3213.
- Tsankov AM, Gu H, Akopian V, Ziller MJ, Donaghey J, Amit I, Gnirke A, Meissner A. 2015. Transcription factor binding dynamics during human ES cell differentiation. *Nature* **518**: 344–349.
- Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, Björklund M, Wei G, Yan J, Niittymäki I, et al. 2009. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. *Nat Genet* **41**: 885–890.
- Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerød A, Kåresen R, Oh DS, Dressler LG, et al. 2004. Mutation of *GATA3* in human breast tumors. *Oncogene* **23**: 7669–7678.
- Van den Boogaard M, Wong LYE, Tessadori F, Bakker ML, Dreizehnter LK, Wakker V, Bezzina CR, 't Hoen PAC, Bakkers J, Barnett P, et al. 2012. Genetic variation in T-box binding element functionally affects *SCN5A/SCN10A* enhancer. *J Clin Invest* **122**: 2519–2530.
- Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. 2009. A census of human transcription factors: function, expression and evolution. *Nat Rev Genet* **10**: 252–263.
- Wang W, Yang J, Liu H, Lu D, Chen X, Zenonos Z, Campos LS, Rad R, Guo G, Zhang S, et al. 2011. Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor γ and liver receptor homolog 1. *Proc Natl Acad Sci* **108**: 18283–18288.
- Wei G-H, Badis G, Berger ME, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, et al. 2010. Genome-wide analysis of ETS-family DNA-binding *in vitro* and *in vivo*. *EMBO J* **29**: 2147–2160.
- White JR, Weston K. 2000. Myb is required for self-renewal in a model system of early hematopoiesis. *Oncogene* **19**: 1196–1205.
- Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. 2013. Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell* **153**: 307–319.
- Wong N, Wang X. 2015. miRDB: an online resource for microRNA target prediction and functional annotations. *Nucleic Acids Res* **43**: D146–D152.
- Yan J, Enge M, Whittington T, Dave K, Liu J, Sur I, Schmiere B, Jolma A, Kivioja T, Taipale M, et al. 2013. Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. *Cell* **154**: 801–813.
- Yang H-M, Do H-J, Kim D-K, Park J-K, Chang W-K, Chung H-M, Choi S-Y, Kim J-H. 2007. Transcriptional regulation of human Oct4 by steroidogenic factor-1. *J Cell Biochem* **101**: 1198–1209.
- Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, Wu C, Karwacz K, Xiao S, Jorgolli M, et al. 2013. Dynamic regulatory network controlling T_H17 cell differentiation. *Nature* **496**: 461–468.
- Young RA. 2011. Control of the embryonic stem cell state. *Cell* **144**: 940–954.
- Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al. 2007. Induced pluripotent stem cell lines derived from human somatic cells. *Science* **318**: 1917–1920.
- Zhang Y, Liu T, Meyer CA, Eickhout J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, et al. 2008. Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**: R137.
- Zhang X, Yalcin S, Lee D-F, Yeh T-YJ, Lee S-M, Su J, Mungamuri SK, Rimmelé P, Kennedy M, Sellers R, et al. 2011. FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. *Nat Cell Biol* **13**: 1092–1099.
- Zhong S, He X, Bar-Joseph Z. 2013. Predicting tissue specific transcription factor binding sites. *BMC Genomics* **14**: 796.
- Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. 2008. *In vivo* reprogramming of adult pancreatic exocrine cells to β -cells. *Nature* **455**: 627–632.
- Zhou Q, Li T, Price DH. 2012. RNA polymerase II elongation control. *Annu Rev Biochem* **81**: 119–143.
- Zhu Y, Richardson JA, Parada LF, Graff JM. 1998. *Smad3* mutant mice develop metastatic colorectal cancer. *Cell* **94**: 703–714.
- Ziller MJ, Edri R, Yaffe Y, Donaghey J, Pop R, Mallard W, Issner R, Gifford CA, Goren A, Xing J, et al. 2014. Dissecting neural differentiation regulatory networks through epigenetic footprinting. *Nature* **518**: 355–359.
- Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Fellmann C, et al. 2011. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. *Genes Dev* **25**: 1628–1640.

Received August 1, 2015; accepted in revised form December 21, 2015.



Models of human core transcriptional regulatory circuitries

Violaine Saint-André, Alexander J. Federation, Charles Y. Lin, et al.

Genome Res. published online February 3, 2016

Access the most recent version at doi:[10.1101/gr.197590.115](https://doi.org/10.1101/gr.197590.115)

Supplemental Material <http://genome.cshlp.org/content/suppl/2016/01/08/gr.197590.115.DC1.html>

P<P Published online February 3, 2016 in advance of the print journal.

Creative Commons License This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genome.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To subscribe to *Genome Research* go to:
<http://genome.cshlp.org/subscriptions>
